[Olaparib Could Be Re-Administered after Chemotherapy].
Gan To Kagaku Ryoho
; 50(4): 473-475, 2023 Apr.
Article
in Ja
| MEDLINE
| ID: mdl-37066460
ABSTRACT
Olaparib, a PARP inhibitor, was approved in 2018 for BRCA1/2 gene mutation and HER2-negative inoperable or recurrent breast cancer with previous chemotherapy. Olaparib is an important drug with minor adverse events compared to chemotherapeutic drugs. In addition, it is expected to exert a high therapeutic effect on breast cancer with BRCA mutations due to its characteristics. We report a case of BRCA2-mutated breast cancer in a patient in whom olaparib was initiated. The patient complained of strong nausea; however, the treatment could be continued by reducing the dose of olaparib to 400 mg and using multiple drugs such as antiemetics and anxiolytics in advance.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Breast Neoplasms
/
Antineoplastic Agents
Limits:
Female
/
Humans
Language:
Ja
Journal:
Gan To Kagaku Ryoho
Year:
2023
Document type:
Article